Global and Japan Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size, Status and Forecast 2020-2026
1 Report Overview
- 1.1 Study Scope
- 1.2 Market Analysis by Type
- 1.2.1 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Growth Rate by Type: 2020 VS 2026
- 1.2.2 Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
- 1.2.3 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
- 1.2.4 Entry and Fusion Inhibitors
- 1.2.5 Protease Inhibitors (PIs)
- 1.2.6 Integrase Inhibitors
- 1.2.7 Coreceptor Antagonists
- 1.3 Market by Application
- 1.3.1 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Share by Application: 2020 VS 2026
- 1.3.2 Hospitals
- 1.3.3 Clinics
- 1.3.4 Labs
- 1.4 Study Objectives
- 1.5 Years Considered
2 Global Growth Trends
- 2.1 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Perspective (2015-2026)
- 2.2 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Growth Trends by Regions
- 2.2.1 Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Regions: 2015 VS 2020 VS 2026
- 2.2.2 Human Immunodeficiency Virus (HIV)-1 Therapeutics Historic Market Share by Regions (2015-2020)
- 2.2.3 Human Immunodeficiency Virus (HIV)-1 Therapeutics Forecasted Market Size by Regions (2021-2026)
- 2.3 Industry Trends and Growth Strategy
- 2.3.1 Market Trends
- 2.3.2 Market Drivers
- 2.3.3 Market Challenges
- 2.3.4 Market Restraints
3 Competition Landscape by Key Players
- 3.1 Global Top Human Immunodeficiency Virus (HIV)-1 Therapeutics Players by Market Size
- 3.1.1 Global Top Human Immunodeficiency Virus (HIV)-1 Therapeutics Players by Revenue (2015-2020)
- 3.1.2 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue Market Share by Players (2015-2020)
- 3.2 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
- 3.3 Players Covered: Ranking by Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue
- 3.4 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Concentration Ratio
- 3.4.1 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Concentration Ratio (CR5 and HHI)
- 3.4.2 Global Top 10 and Top 5 Companies by Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue in 2019
- 3.5 Key Players Human Immunodeficiency Virus (HIV)-1 Therapeutics Area Served
- 3.6 Key Players Human Immunodeficiency Virus (HIV)-1 Therapeutics Product Solution and Service
- 3.7 Date of Enter into Human Immunodeficiency Virus (HIV)-1 Therapeutics Market
- 3.8 Mergers & Acquisitions, Expansion Plans
4 Human Immunodeficiency Virus (HIV)-1 Therapeutics Breakdown Data by Type (2015-2026)
- 4.1 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Historic Market Size by Type (2015-2020)
- 4.2 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Forecasted Market Size by Type (2021-2026)
5 Human Immunodeficiency Virus (HIV)-1 Therapeutics Breakdown Data by Application (2015-2026)
- 5.1 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Historic Market Size by Application (2015-2020)
- 5.2 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Forecasted Market Size by Application (2021-2026)
6 North America
- 6.1 North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size (2015-2026)
- 6.2 North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Type (2015-2020)
- 6.3 North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Application (2015-2020)
- 6.4 North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Country (2015-2020)
- 6.4.1 United States
- 6.4.2 Canada
7 Europe
- 7.1 Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size (2015-2026)
- 7.2 Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Type (2015-2020)
- 7.3 Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Application (2015-2020)
- 7.4 Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Country (2015-2020)
- 7.4.1 Germany
- 7.4.2 France
- 7.4.3 U.K.
- 7.4.4 Italy
- 7.4.5 Russia
- 7.4.6 Nordic
- 7.4.7 Rest of Europe
8 China
- 8.1 China Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size (2015-2026)
- 8.2 China Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Type (2015-2020)
- 8.3 China Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Application (2015-2020)
- 8.4 China Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Region (2015-2020)
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 South Korea
- 8.4.4 Southeast Asia
- 8.4.5 India
- 8.4.6 Australia
- 8.4.7 Rest of Asia-Pacific
9 Japan
- 9.1 Japan Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size (2015-2026)
- 9.2 Japan Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Type (2015-2020)
- 9.3 Japan Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Application (2015-2020)
- 9.4 Japan Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Country (2015-2020)
- 9.4.1 Mexico
- 9.4.2 Brazil
10 Southeast Asia
- 10.1 Southeast Asia Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size (2015-2026)
- 10.2 Southeast Asia Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Type (2015-2020)
- 10.3 Southeast Asia Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Application (2015-2020)
- 10.4 Southeast Asia Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Country (2015-2020)
- 10.4.1 Turkey
- 10.4.2 Saudi Arabia
- 10.4.3 UAE
- 10.4.4 Rest of Middle East & Africa
11 Key Players Profiles
- 11.1 AbbVie, Inc.(U.S.)
- 11.1.1 AbbVie, Inc.(U.S.) Company Details
- 11.1.2 AbbVie, Inc.(U.S.) Business Overview
- 11.1.3 AbbVie, Inc.(U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Introduction
- 11.1.4 AbbVie, Inc.(U.S.) Revenue in Human Immunodeficiency Virus (HIV)-1 Therapeutics Business (2015-2020))
- 11.1.5 AbbVie, Inc.(U.S.) Recent Development
- 11.2 Merck & Co., Inc. (U.S.)
- 11.2.1 Merck & Co., Inc. (U.S.) Company Details
- 11.2.2 Merck & Co., Inc. (U.S.) Business Overview
- 11.2.3 Merck & Co., Inc. (U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Introduction
- 11.2.4 Merck & Co., Inc. (U.S.) Revenue in Human Immunodeficiency Virus (HIV)-1 Therapeutics Business (2015-2020)
- 11.2.5 Merck & Co., Inc. (U.S.) Recent Development
- 11.3 Bristol-Myers Squibb Company (U.S.)
- 11.3.1 Bristol-Myers Squibb Company (U.S.) Company Details
- 11.3.2 Bristol-Myers Squibb Company (U.S.) Business Overview
- 11.3.3 Bristol-Myers Squibb Company (U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Introduction
- 11.3.4 Bristol-Myers Squibb Company (U.S.) Revenue in Human Immunodeficiency Virus (HIV)-1 Therapeutics Business (2015-2020)
- 11.3.5 Bristol-Myers Squibb Company (U.S.) Recent Development
- 11.4 Boehringer Ingelheim GmbH (Germany)
- 11.4.1 Boehringer Ingelheim GmbH (Germany) Company Details
- 11.4.2 Boehringer Ingelheim GmbH (Germany) Business Overview
- 11.4.3 Boehringer Ingelheim GmbH (Germany) Human Immunodeficiency Virus (HIV)-1 Therapeutics Introduction
- 11.4.4 Boehringer Ingelheim GmbH (Germany) Revenue in Human Immunodeficiency Virus (HIV)-1 Therapeutics Business (2015-2020)
- 11.4.5 Boehringer Ingelheim GmbH (Germany) Recent Development
- 11.5 Genentech, Inc. (U.S.)
- 11.5.1 Genentech, Inc. (U.S.) Company Details
- 11.5.2 Genentech, Inc. (U.S.) Business Overview
- 11.5.3 Genentech, Inc. (U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Introduction
- 11.5.4 Genentech, Inc. (U.S.) Revenue in Human Immunodeficiency Virus (HIV)-1 Therapeutics Business (2015-2020)
- 11.5.5 Genentech, Inc. (U.S.) Recent Development
- 11.6 Cipla, Inc. (India)
- 11.6.1 Cipla, Inc. (India) Company Details
- 11.6.2 Cipla, Inc. (India) Business Overview
- 11.6.3 Cipla, Inc. (India) Human Immunodeficiency Virus (HIV)-1 Therapeutics Introduction
- 11.6.4 Cipla, Inc. (India) Revenue in Human Immunodeficiency Virus (HIV)-1 Therapeutics Business (2015-2020)
- 11.6.5 Cipla, Inc. (India) Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
- 13.1 Research Methodology
- 13.1.1 Methodology/Research Approach
- 13.1.2 Data Source
- 13.2 Disclaimer
Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Scope and Market Size
Human Immunodeficiency Virus (HIV)-1 Therapeutics market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Human Immunodeficiency Virus (HIV)-1 Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
Market segment by Type, the product can be split into
Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
Entry and Fusion Inhibitors
Protease Inhibitors (PIs)
Integrase Inhibitors
Coreceptor Antagonists
Market segment by Application, split into
Hospitals
Clinics
Labs
Based on regional and country-level analysis, the Human Immunodeficiency Virus (HIV)-1 Therapeutics market has been segmented as follows:
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of Middle East & Africa
In the competitive analysis section of the report, leading as well as prominent players of the global Human Immunodeficiency Virus (HIV)-1 Therapeutics market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.
The key players covered in this study
AbbVie, Inc.(U.S.)
Merck & Co., Inc. (U.S.)
Bristol-Myers Squibb Company (U.S.)
Boehringer Ingelheim GmbH (Germany)
Genentech, Inc. (U.S.)
Cipla, Inc. (India)
...